Avoidance and management of positive surgical margins before, during and after radical prostatectomy

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 4, 2002, Pages 252-263

  Bott, Simon R J ^a   Kirby, R S ^b  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Prevention; Prostate cancer; Prostatectomy; Surgical margins; Treatment

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLOSTOMY; CYSTITIS; EARLY DIAGNOSIS; GYNECOMASTIA; HUMAN; INTRAOPERATIVE PERIOD; LAPAROSCOPIC SURGERY; MALE; MASTALGIA; ORCHIECTOMY; OSTEOPOROSIS; PATIENT CARE; PATIENT SELECTION; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SENSITIVITY ANALYSIS; SURGICAL APPROACH; SURGICAL TECHNIQUE; TIME; URINARY DIVERSION;

ADENOCARCINOMA; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; COMBINED MODALITY THERAPY; HUMANS; LAPAROSCOPY; MALE; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, HORMONE-DEPENDENT; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 0036965583     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500612     Document Type: Review

References (118)

1. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355: 1788-1789.
2. Epstein JL, Walsh PC, Carmichael M, Brendler CB. Pathological and clinical findings to predict tumour extent of non-palpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374.
3. Catalona WJ, Bigg SW. Nerve sparing prostatectomy: evaluation of results in 250 patients. J Urol 1990; 143: 538-543.
4. Ohori M et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995; 154: 1818-1824.
5. Ackerman DA et al. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993; 150: 1845-1850.
6. Gomez CA, Soloway MS, Civantos F, Hachiya T. Bladder neck preservation and its impact on positive surgical margins during radical prostatectomy. Urology 1993; 42: 689-693.
7. Watson RB, Civantos F, Soloway MS. Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology 1996; 48: 80-90.
8. Epstein JI. Evaluation of radical prostatectomy capsular margins of resection. The significance as negative, closely approaching, and positive. Am J Surg Pathol 1990; 14: 626-632.
9. Stamey TA et al. Positive surgical margins at radical prostatectomy: importance of apical dissection. J Urol 1990; 143: 1166-1172.
10. Blute ML et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology 1997; 50: 733-739.
11. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumours found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 1994; 152: 1721-1729.
12. Van Poppel H et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomised trial. J Urol 1995; 154: 429.
13. Blute ML et al. Pathologic classification of prostate cancer. The impact of margin status. Cancer 1998; 82: 902-908.
14. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-3593.
15. Sakr WA et al. International Consultation on Prostatic Intraepithelial Neoplasia and Pathologic Staging of Prostate Cancer. Workgroup 2: Staging and reporting of prostate cancer-sampling of the radical prostatectomy specimen. Cancer 1996; 78: 366-368.
16. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996; 20: 286-294.
17. Van den Ouden D, Bentvelsen FM, Boevé ER, Schroder FH. Positive surgical margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol 1993; 72: 489-494.
18. Cheng L et al. Correlation of margin status and extracapsular extension with progression of prostate cancer. Cancer 1999; 86: 1775-1782.
19. Lowe BA, Lieberman SF. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 1997; 158(4): 1452-1456.
20. Grossfeld GD et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CAPSURE database. J Urol 2000; 163: 1171-1177.
21. Stamey TA et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395.
22. Grossfeld GD et al. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol 2000; 164: 93.
23. Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998; 160: 299-315.
24. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life after anatomic radical retropubic prostatectomy results at 10 years. J Urol 1994; 152: 1831-1836.
25. Hall GS, Kramer CE, Epstein JI. Evaluation of radical prostatectomy specimens. A comparative analysis of sampling methods. Am J Surg Pathol 1992; 16: 315.
26. Ayala AG et al. The prostate capsule: does it exist? Its importance in the staging and treatment of prostate carcinoma. Am J Surg Pathol 1989; 13: 21-27.
27. Weldon VE, Tavel FR, Neuwirth H, Cohen R. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 1995; 153: 1565.
28. Epstein JI et al. Disease progression following radical prostatectomy in men with Gleason score 7 tumour. J Urol 1998; 160: 97-101.
29. True LD. Surgical pathology examination of the prostate gland. Practice survey by American society of clinical pathologists. Am J Clin Pathol 1994; 102(5): 572-579.
30. Partin AW et al. Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localised prostate cancer. JAMA 1997; 277: 1445-1451.
31. D'Amico AV et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathological stage, margin status and postoperative prostate-specific antigen failure in patient with clinically organ-confined prostate cancer. J Clin Oncol 1996; 14: 1770-1777.
32. Zincke H et al. Long term (15 years) results after radical prostatectomy for clinically localised (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-1857.
33. Stovsky MD, Reznicek M. The diagnosis prevention and treatment of margin positive disease after radical prostatectomy for adenocarcinoma of the prostate. AUA Update Ser 1997; 16: 58.
34. Wahl S et al. Incidence of surgical margin involvement in various forms of radical prostatectomy. Urology 1990; 36: 23-26.
35. Hammerer P, Henke P, Meyer-Moldenhauer WH, Huland H. Preoperative evaluation of tumour aggressiveness in patients with localised prostate carcinoma. J Urol pt 2 1995; 153: 428A (abstract 798).
36. Ohori M et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 1843-1849.
37. Ross JS et al. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. Am J Surg Pathol 1999; 23(3): 296-301.
38. Lerner SE et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996; 156: 137-143.
39. Bostwick DG et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 1999; 124: 995-1000.
40. Powell IJ et al. The predictive value of race as a clinical prognostic factor among patients with clinically localised prostate cancer: a multivariate analysis of positive surgical margins. Urology 1997; 49: 726-731.
41. Shekarriz B et al. Impact of location and multifocality of positive surgical margins on disease-free survival following radical prostatectomy: a comparison between African-American and white men. Urology 2000; 55: 899-903.
42. Cornud F et al. Endorectal color doppler sonography and endorectal MR imaging features in nonpalpable prostate cancer: correlation with radical prostatectomy findings.Am J Radiol 2000; 174(4): 1161-1168.
43. D'Amico AV et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localised prostate cancer. J Urol 2000; 164: 759-763.
44. Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin N Am 2000; 38: 59-85.
45. Huncharek M, Muscat J. Serum prostate specific antigen as a predictor of staging abdominal/ pelvic computerised tomography in newly diagnosed prostate cancer. Abdom Imag 1996; 21: 364-367.
46. Manyak MJ, Javitt MC. The role of computerised tomography, magnetic resonance imaging, bone-scan and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. Sem Urol Oncol 1998; 16: 145-152.
47. Ikonen S Karkkainen P et al. Magnetic resonance imaging of clinically localised prostate cancer. J Urol 1998; 159: 915-919.
48. Hoh CK et al. Positron emission tomography in urological oncology. J Urol 1998; 159(2): 342-356.
49. Kotzertke J et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nuc Med 2000; 27(9): 1415-1419.
50. De Grado TR et al. Synthesis and evaluation of 18F-labelled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61(1): 110-117.
51. Frazier HA, Robertson JE, Paulson DF. Radical prostatectomy: the pros and cons of the perineal versus retropubic approach. J Urol 1992; 147: 888-890.
52. Guillonneau B, Vallancian G. Laparoscopic radical prostatectomy: the Montsouris experience. J Urol 2000; 163: 418-422.
53. Abbou CC et al. Laparoscopic radical prostatectomy: preliminary results. Urology 2000; 55: 630-634.
54. Epstein JI. Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin N Am 1996; 23(4): 651-663.
55. Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998; 160: 2418-2424.
56. Lowe BA. Comparison of bladder neck preservation to bladder neck resection in maintaining post prostatectomy urinary continence. Urology 1996; 48(6): 889-893.
57. Licht MR, Klein EA, Tuason L, Levin H. Impact of bladder neck preservation during radical prostatectomy on continence and cancer control. Urology 1994; 44(6): 883-887.
58. Shelfo SW, Obek C, Soloway MS. Update on bladder neck preservation during radical retropubic prostatectomy: impact on pathologic outcome, anastomotic strictures and continence. Urology 1998; 51(1): 73-78.
59. Poon M et al. Radical retropubic prostatectomy: bladder neck preservation versus reconstruction. J Urol 2000; 163(1): 194-198.
60. Walsh PC. Radical retropubic prostatectomy. In: Cambell's Urology, 6th edn, ed. PC Walsh, AB Retnik, TA Stamey & AD Vaughan Jr., WB Saunders: Philadelphia, PA, 1992, pp 2865-2886.
61. Catalona WJ, Bigg SW. Nerve sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 1990; 143: 538.
62. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982; 128: 492-497.
63. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate specific antigen after anatomic radical retropubic prostatectomy. Urol Clin N Am 1997; 24(2): 395-406.
64. Rosen MA et al. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992; 148: 331.
65. Eggleston JC, Walsh PC. Radical prostatectomy with preservation of sexual function: pathological findings in the first 100 cases. J Urol 1985; 134: 1146-1148.
66. Catalona WJ, Dresner SM. Nerve sparing radical prostatectomy: extraprostatic extension and preservation of erectile function. J Urol 1985; 134: 1149.
67. Daniels GF, McNeil JE, Stamey TA. Predictive value of contralateral biopsies in unilaterallly palpable prostate cancer. J Urol 1992; 147: 870-874.
68. Catalona WJ. Patient selection for, results of, and impact on tumour resection of potency-sparing radical prostatectomy. Urol Clin N Am 1990; 17: 819.
69. Villers A et al. The role of perineural space invasion in the local spread of prostate adenocarcinoma. J Urol 1989; 142: 763.
70. Jones EC. Resection margin status in radical retropubic prostatectomy specimens: relationship of type of operation, tumour size, tumour grade and local tumour extension. J Urol 1990; 144: 89-93.
71. Stephenson RA, Middleton RG, Abbott TM. Wide excision (non nerve sparing) radical retropubic prostatectomy using an initial perirectal dissection. J Urol 1997; 157: 251-256.
72. Smith RC, Partin AW, Epstein JI, Brendler CB. Extended follow up of the influences of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localised prostate cancer and extensive capsular penetration. J Urol 1996; 156: 454.
73. Graefen M et al. Incidence of positive surgical margins after biopsy-selected nerve sparing radical prostatectomy. Urology 1998; 51(3): 437-442.
74. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831-1836.
75. Soloway MS, Neulander E. Bladder-neck preservation during radical prostatectomy. Sem Urol Oncol 2000; 18(1): 51-56.
76. Voges G et al. The predictive significance of substaging stage A prostate cancer (A1 vs A2) for volume and grade of total cancer in the prostate. J Urol 1992; 147: 858.
77. Montironi R et al. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study. Pathol Res Pract 1999; 195(4): 201-208.
78. Soloway M, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Beaz A. Randomised prospective study comparing radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bN × M0) prostate cancer. J Urol 1995; 154: 424-428.
79. Van Poppel H et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the incidence of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomised trial. J Urol 1995; 154: 429.
80. Goldenberg SL et al. A randomised prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localised prostate cancer. J Urol 1996; 156: 873-879.
81. Witjies WP, Schulmann CC, Debruyne FM. Preliminary results of a prospective randomised study comparing radical prostatectomy alone versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0M0 prostatic carcinoma. Urology 1997 (Suppl); 49: 65-69.
82. Goldenberg S et al. A randomised trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24 month post-treatment PSA results. J Urol pt 2 1997; 157: 92 (abstract 357).
83. Soloway M et al. Radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in cT2b prostate cancer-24 month results. J Urol pt 2 1997; 157: 160 (abstract 619).
84. Lee HH, Warde P, Jewett MA. Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int 1999; 83(4): 438-448.
85. Takayama TK, Lange PH. Radiation therapy for local recurrence of prostate cancer after radical prostatectomy. Urol Clin N Am 1994; 21(4): 687-700.
86. Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1996; 47: 232.
87. Walsh PC, Cadeddu JA, Partin AW, DeWeese TL. Long-term results of radiation therapy for isolated PSA elevation following radical prostatectomy. J Urol pt 2 1997; 157: 94 (abstract 363).
88. Zincke H et al. Long-term (15 years) results after radical prostatectomy for clinically localised (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850.
89. Pound CR et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin N Am 1997; 24: 395.
90. Kupelain PA et al. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37: 1043.
91. Catton C, Gospodarowicz M, Warde P, Panzarella T, Catton P, McLean M, Milosevic M. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 2001; 59(1): 51-60.
92. Anscher MS, Robertson CN, Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten year update. Int J Radiat Oncol Biol Phys 1995; 33: 37.
93. Leibovich BC et al. Benefit of adjuvant radiation therapy for localised prostate cancer with a positive surgical margin. J Urol 2000; 163: 1178-1182.
94. Vicini FA et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 1999; 54: 111-117.
95. Peschel RE et al. PSA based review of adjuvant and salvage radiation therapy vs observation in postoperative prostate cancer patients. Int J Cancer 2000; 90: 29-36.
96. Van Poppel H et al. Is postoperative irradiation after radical prostatectomy necessary? Eur J Cancer 1999; 35: 1763-1770.
97. Jacobson GM, Smith JA Jr, Stewart JR. Postoperative radiation therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 1987; 13: 1021.
98. Meier R et al. Postoperative radiation therapy after radical prostatectomy for prostate carcinoma. Cancer 1992; 70: 1960.
99. Gibbons R et al. Adjuvant radiotherapy following radical prostatectomy: results and complications. J Urol 1986; 135: 65-68.
100. Cheng W et al. Radical prostatectomy for stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 1993; 42: 283.
101. Cox J et al. Consensus statements on radiation therapy on prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999; 17: 1155.
102. Nudell D et al. Radiotherapy after radical prostatectomy: treatment outcomes and patterns of failure. Urology 1999; 54: 1049-1057.
103. Billis A et al. Vas deferens involvement in radical prostatectomies. Prevalence and significance. United States and Canadian Academy of Pathology AGM. Chicago, IL, 2002. Abstract 647, 155A.
104. Cadeddu JA et al. Long-term results for radiation for prostate cancer recurrence following radical prostatectomy. J Urol 1998; 159:173-177.
105. Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 1997; 337: 295-300.
106. Petrovich Z et al. Comparisons of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate. Am J Clin Oncol 1999; 22: 323-331.
107. Fomenti SC et al. Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve sparing prostatectomy. Urology (Online) 2000; 56(3): 453-458.
108. Early Breast Cancer Trialists Collaborative Group. Systemic treatment by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 1-15.
109. Zincke H, Utz DC, Taylor WF. Bilateral pelvic lymphadenectomy for clinical stage C prostatic carcinoma: role of adjuvant treatment for residual carcinoma and disease progression. J Urol 1986; 135: 1199-1205.
110. Messing EM, Manola J, Sarodsy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men ith node-positive prostate cancer. New Engl J Med 1999; 341(24): 1781-1788.
111. Chay C, Smith DC. Adjuvant and neoadjuvant therapy in prostate cancer. Sem Oncol 2001; 28(1): 3-12.
112. Prayer-Galetti T, Zattoni F, Capizzi A et al. Disease free survival in patients with pathological 'C Stage' prostate cancer at radical prostatectomy submitted to adjuvant hormonal treatment. Eur Urol 2000; 38: 504 (abstract 48).
113. Wirth M et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001; 58(2): 146-151.
114. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281(17): 1591-1597.
115. Lawton CA et al. Updated results of the phase ??? Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49(4): 937-946.
116. Eulau SM et al. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy. Int J Radiat Oncol Biol Phys 1998; 41: 735-740.
117. Anscher MS, Prosnitz LR. Multivariate analysis of factors predicting local relapse after radical prostatectomy - possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1991; 21: 941-947.
118. Meng MV, Carroll PR. Local therapy for prostate-specific antigen recurrence after definitive treatment. Prostate Cancer Prostat Dis 2001; 4: 1-8.